• Explore /
  • Poster
  • / ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.

ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.

Abstract Poster

Authors

Ignace Vergote

Ignace Vergote

University Hospitals Leuven, Leuven Cancer Institute, and BGOG, Leuven, Belgium

Ignace Vergote , Mansoor R. Mirza , Robert L. Coleman , Jose Alejandro Perez-Fidalgo , Bradley J. Monk , Giorgio Valabrega , Brian M. Slomovitz , Toon Van Gorp , Kathleen N. Moore , Jalid Sehouli , David Cibula , Tally Levy , Gerasimos Aravantinos , Kai Li , Pratheek Kalyanapu , Vicky Makker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT05611931

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5627)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5627

Abstract #

TPS5627

Poster Bd #

314b

Abstract Disclosures

Similar Posters

First Author: Ignace Vergote

First Author: Brian M. Slomovitz

First Author: Seock-Ah Im

First Author: Mansoor Raza Mirza